ADVENTRX Pharmaceuticals, Inc. Reports Fourth Quarter and Full Year 2008 Financi...(lion increase in expenses related to ext...)

Date:3/25/2009

lion increase in expenses related to external research-related manufacturing and regulatory and quality assurance activities related to ANX-530 and ANX-514, a $1.3 million increase in external clinical trial expenses related to ANX-514 and a $0.2 million increase in personnel costs, offset by a $5.4 million decrease in external clinical trial expenses related to CoFactor and ANX-530 and a $0.3 million decrease in non-cash, stock-based compensation expenses. R&D expenses for 2008 included non-cash, stock-based compensation expenses amounting to $0.7 million, compared to $1.0 million for 2007.

SG&A expenses increased by $1.0 million, or 12%, to $9.7 million for 2008, from $8.7 million for 2007. The increase was substantially due to a $0.7 million increase in severance expenses, a $0.4 million increase for consulting expenses related to market research, a $0.3 million increase in personnel expenses and $0.1 million increase in professional services, offset by a $0.5 million decrease in non-cash, stock-based compensation expenses. SG&A expenses for 2008 included non-cash, stock-based compensation expenses amounting to $0.9 million, compared to $1.4 million for 2007.

Revenue of $500,000 in 2008 represents a portion of a settlement payment from Theragenex, LLC. In May 2008, we settled a dispute with Theragenex arising out of its alleged breach of a license agreement and, in accordance with such settlement, Theragenex paid us $0.6 million. We recognized $0.5 million as revenue, and the remainder, $0.1 million, as other income.

Interest income and other income amounted to $0.7 million for 2008, compared to $2.2 million in 2007. The decrease in interest income and other income was primarily attributable to lower interest income based on lower invested balances, offset by $0.1 million received as part of the Theragenex settlement, which was recorded as other income.

Balance Sheet Hi
'/>"/>

SOURCE ADVENTRX Pharmaceuticals, Inc. Copyright©2009 PR Newswire. All rights reserved

0 GOOD

Page: 1 2 3 4 5 6 7
Related biology technology :

1. ADVENTRX Announces Further Cost-Cutting Measures
2. ADVENTRX Provides Update on Strategic Transaction Process
3. ADVENTRX Announces Further Cost-Cutting Measures
4. ADVENTRX Exploring Strategic Options
5. ADVENTRX Pharmaceuticals Reports Third Quarter 2008 Financial Results and Business Update
6. ADVENTRX Pharmaceuticals to Present at the Rodman & Renshaw 10th Annual Global Healthcare Conference
7. ADVENTRX Announces Restructuring and Cost Reduction Initiatives
8. ADVENTRX Pharmaceuticals to Report Second Quarter 2008 Results
9. ADVENTRX Settles Dispute With Former Licensee
10. ADVENTRX Pharmaceuticals to Present at the Rodman & Renshaw 5th Annual Global Healthcare Conference
11. ADVENTRX Appoints Vice President of Manufacturing